

1
2
3
4

TITLE PAGE
- Food Science of Animal Resources -
Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
Article Type	Short Communication
Article Title	Integrative analysis of probiotic-mediated remodeling in canine gut microbiota and metabolites using a fermenter for an intestinal microbiota model
Running Title (within 10 words)	Effect of probiotics on gut microbiome using FIMM
Author	Anna Kang ¹ , Min-Jin Kwak ¹ , Hye Jin Choi ¹ , Seon-hui Son ¹ , Sei-hyun Lim ¹ , Ju Young Eor ¹ , Minho Song ² , Min Kyu Kim ² , Jong Nam Kim ³ , Jungwoo Yang ⁴ , Minjee Lee ⁴ , Minkyong Kang ⁵ , Sangnam Oh ^{5*} , and Younghoon Kim ^{1*}
Affiliation	1 Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul National University, Seoul 08826, Korea 2 Department of Animal Science and Biotechnology, Chungnam National University, Daejeon 34134, Korea 3 Department of Food Science & Nutrition, Dongseo University Busan 47011, Korea 4 IBS R&D Center, Ildong Bioscience, Pyeongtaek-si 17957, Gyeonggi-do, Korea 5 Department of Functional Food and Biotechnology, Jeonju University, Jeonju 55069, Korea
Special remarks – if authors have additional information to inform the editorial office	
ORCID (All authors must have ORCID) https://orcid.org	Anna Kang (0000-0003-0208-6234) Min-Jin Kwak (0000-0001-9832-3251) Hye Jin Choi (0000-0002-5977-2780) Seon-hui Son (0009-0000-0721-1407) Sei-hyun Lim (0009-0003-0039-6420) Ju Young Eor (0000-0002-3764-3339) Minho Song (0000-0002-4515-5212) Min Kyu Kim (0000-0002-9259-8219) Jong Nam Kim (0000-0002-8034-7156) Jungwoo Yang (0000-0003-3836-729X) Minjee Lee (0000-0002-0594-5279) Minkyong Kang (0000-0002-2366-7970) Sangnam Oh (0000-0002-2428-412x) Younghoon Kim (0000-0001-6769-0657)
Conflicts of interest List any present or potential conflict s of interest for all authors. (This field may be published.)	The authors declare no potential conflict of interest.
Acknowledgments State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available. (This field may be published.)	This research was supported by Ildong Bioscience Co., Ltd. (2022) and by the National Research Foundation of Korea Grant, funded by the Korean government (MEST) (NRF-2021R1A2C3011051) and by the support of "Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ015865)" Rural Development Administration, Republic of Korea.
Author contributions (This field may be published.)	Conceptualization: Kang A, Kwak MJ, Oh S, Kim Y Data curation: Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY, Song M, Kim MK, Kim JN, Yang J, Lee M, Oh S, Kim Y Formal analysis: Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY Methodology: Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY Software: Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY Validation: Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY, Song M, Kim MK, Kim JN, Yang J, Lee M, Oh S, Kim Y Investigation: Oh S, Kim Y Writing - original draft: Kang A, Kwak MJ, Oh S, Kim Y

	Writing - review & editing: : Kang A, Kwak MJ, Choi HJ, Son SH, Lim SH, Eor JY, Song M, Kim MK, Kim JN, Yang J, Lee M, Oh S, Kim Y (This field must list all authors)
Ethics approval (IRB/IACUC) (This field may be published.)	This animal experiment was conducted with the approval of the Institutional Animal Care and Use Committee (IACUC) at Chungnam National University (202109A-CNU-149).

5

6 **CORRESPONDING AUTHOR CONTACT INFORMATION**

For the <u>corresponding</u> author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Younghoon Kim
Email address – this is where your proofs will be sent	ykeys2584@snu.ac.kr
Secondary Email address	
Postal address	Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul National University, Seoul 08826, Korea
Cell phone number	
Office phone number	+82-02-880-4808
Fax number	+82-02-873-2271

7

8

11
12 **Integrative analysis of probiotic-mediated remodeling in canine gut**
13 **microbiota and metabolites using a fermenter for an intestinal microbiota**
14 **model**

15
16 Anna Kang^{1†}, Min-Jin Kwak¹, Hye Jin Choi¹, Seon-hui Son¹, Sei-hyun Lim¹, Ju Young Eor¹, Minho
17 Song², Min Kyu Kim², Jong Nam Kim³, Minjee Lee⁴, Jungwoo Yang⁴, Sangnam Oh^{5*}, and Younghoon
18 Kim^{1*}

19
20 ¹*Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul*
21 *National University, Seoul 08826, Korea*

22 ²*Department of Animal Science and Biotechnology, Chungnam National University, Daejeon 34134,*
23 *Korea*

24 ³*Department of Food Science & Nutrition, Dongseo University Busan 47011, Korea*

25 ⁴*IBS R&D Center, Ildong Bioscience, Pyeongtaek-si 17957, Gyeonggi-do, Korea*

26 ⁵*Department of Functional Food and Biotechnology, Jeonju University, Jeonju 55069, Korea*
27

28
29
30 *To whom correspondence should be addressed: osangnam@jj.ac.kr and ykeys2584@snu.ac.kr
31

Abstract

In contemporary society, the rising number of pet-owning households has significantly heightened interest in companion animal health, catalyzing the expansion of the probiotics market aimed at enhancing pet well-being. This burgeoning interest has propelled research into the gut microbiota of companion animals, although the breadth of research in this area is still evolving. Given the ethical and societal challenges associated with experiments on highly intelligent and pain-sensitive animals, there is an imperative need for alternative research methodologies that diminish reliance on live animal testing. Against this backdrop, the Fermenter for Intestinal Microbiota Model (FIMM) is investigated as a practical in vitro tool designed to replicate the gastrointestinal conditions of living animals in this study, offering a means to study the gut microbiota while minimizing animal experimentation. The FIMM system was employed to explore the interactions between intestinal microbiota and probiotics within a simulated gut environment. Two strains of commercial probiotic bacteria, *Enterococcus faecium* IDCC2102 and *Bifidobacterium lactis* IDCC4301, along with a newly isolated strain from domestic dogs, *Lactobacillus acidophilus* SLAM AK001, were introduced into the FIMM system in conjunction with the gut microbiota from a beagle model. Findings underscore the system's capacity to effectively mirror and modulate the gut environment, evidenced by a marked increase in beneficial bacteria like *Lactobacillus* and *Faecalibacterium* and a decrease in the opportunistic pathogen *Clostridium*. This study also verified the system's ability to facilitate accurate interactions between probiotics and commensal bacteria, demonstrated by the expected production of short-chain fatty acids and critical bacterial metabolites, including amino acids and GABA precursors. Thus, the results advocate for the application of FIMM as an in vitro cultivation system that authentically simulates the intestinal environment, presenting a viable alternative for examining the dynamics of gut microbiota and metabolites in companion animals.

Keywords: in vitro culturomics; lactic acid bacteria; canines; FIMM; microbiome

Introduction

57

58

59 The gut microbiome, an intricate community of microorganisms inhabiting the gastrointestinal tracts of
60 animals, exerts a profound influence on the health and well-being of its hosts. The critical role of the gut
61 microbiome in human health has been well-documented, leading to a parallel increase in research focusing
62 on the microbiological aspects of both industrial and domestic animal health (Lee et al., 2023; Song et al.,
63 2023). This burgeoning field, situated at the intersection of microbiology and veterinary science, explores
64 how dietary components, particularly probiotics, influence the gut microbiota, contributing to enhanced
65 health and growth in animals (Lee et al., 2022b; Quinn et al., 2015). The incorporation of probiotics into
66 pet diets aims not only to maintain a balanced microbial ecosystem but also to enhance immune function
67 and provide therapeutic benefits in various conditions, including gastrointestinal disorders and resistance
68 to antibiotics. The rising awareness of these benefits has spurred a notable expansion in the probiotics
69 market, tailored to meet the nutritional needs of companion animals, with a significant emphasis on gram-
70 positive bacterial strains like *Bacillus*, *Enterococcus*, *Lactobacillus*, *Pediococcus*, and *Streptococcus* (Harel
71 and Tang, 2023; Lee et al., 2022a; Mugwanya et al., 2021).

72 Despite the valuable insights gained from animal-based microbiological research, such studies are
73 fraught with ethical, logistical, and financial challenges (Lee et al., 2022a; Mun et al., 2021). The ethical
74 debate surrounding animal experimentation, especially with animals that exhibit high levels of intelligence
75 and sensitivity to pain, underscores the necessity for humane and sustainable research methodologies.
76 Additionally, the limitations inherent in animal models, particularly in their ability to accurately replicate
77 complex human diseases or conditions, highlight the need for innovative research approaches that can offer
78 reliable and ethically sound alternatives.

79 In response to these challenges, this study introduces the Fermenter for Intestinal Microbiota Model
80 (FIMM), an advanced in vitro tool engineered to replicate the physiological conditions of the animal
81 gastrointestinal tract, including optimal pH, temperature, and residence time. The FIMM system offers a
82 distinctive platform for examining the interactions between probiotics and gut microbiota under controlled

83 conditions, allowing for the exploration of these intricate relationships without the ethical and logistical
84 complexities associated with live animal testing.

85 In this study, a meticulous selection of probiotic strains was employed to elucidate the operational
86 dynamics of the FIMM system. Two commercial probiotic strains, *Enterococcus faecium* IDCC2102 and
87 *Bifidobacterium lactis* IDCC4301 (Kang et al., 2024), along with *Lactobacillus acidophilus* SLAM AK001
88 (Kang et al., 2022), a strain newly isolated from domestic dogs, were integrated into the FIMM system.
89 This integration was performed alongside gut microbiota sourced from a laboratory beagle model, selected
90 for its uniform living conditions, diet, and species consistency, which are crucial for minimizing
91 experimental variability. The incorporation of diverse probiotic species aims to provide a comprehensive
92 understanding of the FIMM's capability to simulate the canine gastrointestinal environment accurately. This
93 approach is designed to not only test the system's efficacy in replicating complex gut microbial interactions
94 but also to evaluate the potential influence of these probiotics on the gut microbiota within a controlled, in
95 vitro setting. Through this strategic selection of probiotic strains and a well-defined animal model, the study
96 endeavors to enhance the precision and applicability of the FIMM, contributing valuable insights into the
97 interplay between probiotics and gut microbiota, and ultimately facilitating the development of more
98 targeted and effective strategies for animal health and nutrition.

99

Materials and Methods

100

101

102 **Bacterial cultivation and study design**

103 In this study, fecal samples were collected from domestic canines (n=3; Maltese and Jindo) aged
104 between 6-8 years old. These samples were subsequently pooled for analysis. The strain *Lactobacillus*
105 *acidophilus* SLAM AK001 (LA), isolated from domestic canines, was identified in a prior investigation
106 (Kang et al., 2022). Additionally commercial strains *Enterococcus faecium* IDCC 2102 (*E.faecium*
107 IDCC2102) and *Bifidobacterium lactis* IDCC4301 (*B. lactis* IDCC 4301) were supplied by ILDONG
108 Bioscience CO., LTD (Gyeonggi-do, Republic of Korea). To culture these probiotic strains, de Man,
109 Rogosa & Sharpe (MRS; BD Difco, Franklin Lakes, NJ, USA) medium was utilized. The culturing process
110 lasted 48 hours at a temperature of 37 °C under aerobic conditions. The collection of samples and
111 subsequent experimentation involving domestic canines and laboratory-raised beagles were carried out with
112 the endorsement of the Institutional Animal Care and Use Committee (IACUC) at Chungnam National
113 University (202109A-CNU-149).

114

115 **Culturomic analysis**

116 In this research, culturomic and metagenomic techniques were employed to identify prevalent lactic acid
117 bacteria within the gut microbiota of domestic dogs, specifically Maltese and Jindo breeds (n = 3), aged
118 between 6 to 8 years. Fecal samples were meticulously collected, with 10 grams from each sample being
119 aseptically transferred into a sample bag (3 M, St. Paul, MN, USA). Each sample was then diluted with 90
120 mL of 0.1% buffered peptone water (Oxoid, Hampshire, UK) and subjected to homogenization by
121 stomaching for two minutes at speed level 10. The resulting homogenate was serially diluted and inoculated
122 onto various selective media, including MRS (BD Difco), phenylethyl alcohol agar (PEA; BD Difco), and
123 *Bifidobacterium* selective agar (BS; BD Difco) plates, which were further enriched with 7.5% Bacto™
124 Agar medium (BD Difco). These plates were incubated under both aerobic and anaerobic conditions at
125 37 °C for 48 hours to promote bacterial growth (Cho et al., 2022; Choi et al., 2016; Sornplang and
126 Piyadeatsoontorn, 2016). The lactic acid bacteria isolated were then prepared for further experimental use,

127 underpinning the study's objective to explore the gut microbiota dynamics and probiotic interactions within
128 the FIMM system.

129

130 **Fermenter for intestine microbiota model (FIMM)**

131 The Fermenter for Intestinal Microbiota Model (FIMM) is an advanced in vitro system designed to
132 simulate the canine gastrointestinal environment, facilitating detailed studies of gut microbiota interactions.
133 This system was developed based on methodologies outlined in our previous study (Kang et al., 2022), and
134 took inspiration from the well-established Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
135 model (Van de Wiele et al., 2015). For the incubation of canine fecal samples within the FIMM system,
136 pooled feces of laboratory raised beagles (n=6) were aseptically homogenized in filter bags using a
137 stomacher (JumboMix, Interscience, Saint Nom, France). Following homogenization, the supernatant was
138 collected and introduced into the FIMM medium at a 10% inoculation rate. Concurrently, the selected
139 probiotics—*Lactobacillus acidophilus* SLAM AK001, *Enterococcus faecium* IDCC2102, and
140 *Bifidobacterium lactis* IDCC4301—were inoculated to achieve a final concentration of 1% within the
141 system. The FIMM medium employed in these experiments was based on a modified Gifu Anaerobic
142 Medium (mGAM; HIMEDIA, DB Maarn, Netherlands), recognized for its suitability in cultivating
143 anaerobic bacteria (Javdan et al., 2020). To closely mimic the conditions of the canine gut, the medium's
144 pH was adjusted to 7.3, and the temperature was maintained at 38°C, aligning with the physiological
145 parameters noted in canine intestinal research (Sagawa et al., 2009; Tochio et al., 2022). Through this
146 meticulous replication of the canine gut environment, the FIMM system provides a robust platform for
147 investigating the complex dynamics of gut microbiota and the impact of probiotics on gastrointestinal health.

148

149 **Metagenomic analysis**

150 After the FIMM incubation, the cultivates were collected, and genomic DNA was extracted with the
151 DNeasy PowerSoil Pro Kit (Qiagen, Hilden, Germany). The 16S rRNA gene, including the V4 region, was
152 amplified, and the PCR product was sequenced using iSeq 100 (Illumina, Inc. San Diego, CA, USA)
153 following the manufacturer's protocols. The amplicon primer sequences were as follows: 515F,

154 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA; 806R,
155 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT for the 16S
156 rRNA gene including the V4 region. The correlations and taxonomy of the obtained pair-end sequences
157 were analyzed using Mothur v. 4.18.0 following the standard operating procedure suggested by the Schloss
158 laboratory (Kozich et al., 2013; Son et al., 2021) and demonstrated using GraphPad Prism v. 9.4.1
159 (GraphPad Software, LLC, San Diego, CA, USA). For the comparative analysis, the study utilized alpha
160 diversity metrics, notably the Chao and Shannon indices, to reveal patterns of relative abundance across
161 different groups. This approach provided a deeper understanding of microbial diversity. Additionally,
162 Principal Coordinates Analysis (PCoA) diagrams, based on both weighted and unweighted UniFrac
163 distances, were developed to illustrate the spatial distribution of the fecal microbiome samples.

164

165 **Metabolomic analysis**

166 The samples were cultivated in triplicate on FIMM medium before being separated into pellets for
167 metagenomics analysis and supernatants for metabolite analysis. A PVDF syringe filter with a pore size of
168 0.2 μm was used to filter the supernatants. Samples of 200 μL of the filtered supernatant were dried in a
169 vacuum concentrator and kept at $-81\text{ }^{\circ}\text{C}$ for GC-MS analysis. Derivatization of the extract involved 30 μL
170 of 20 mg/mL methoxyamine hydrochloride in pyridine (Sigma) at $30\text{ }^{\circ}\text{C}$ for 90 min, followed by 50 μL of
171 N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA; Sigma) at $60\text{ }^{\circ}\text{C}$ for 30 min. The internal standard
172 fluoranthene was added to the extract. A Thermo Trace 1310 GC (Waltham, MA, USA) and Thermo ISQ
173 LT single quadrupole mass spectrometer were used for GC-MS analysis. A 60-m DB-5MS column
174 (Agilent, Santa Clara, CA, USA) with 0.2-mm i.d. A 0.25- μm film thickness was utilized for separation.
175 The sample was injected at $300\text{ }^{\circ}\text{C}$ with a 1:60 split ratio and 90 mL/min helium split flow for analysis. The
176 metabolites were separated using 1.5 mL continuous flow helium in an oven ramp from $50\text{ }^{\circ}\text{C}$ (2 min hold)
177 to $180\text{ }^{\circ}\text{C}$ (8 min hold) at $5\text{ }^{\circ}\text{C}/\text{min}$, $210\text{ }^{\circ}\text{C}$ at $2.5\text{ }^{\circ}\text{C}/\text{min}$, and $325\text{ }^{\circ}\text{C}$ (10 min hold) at $5\text{ }^{\circ}\text{C}/\text{min}$. The mass
178 spectra were obtained at 5 spectra per second from 35-650 m/z. Electron impact and $270\text{ }^{\circ}\text{C}$ ion source
179 temperature were used in ionization mode. The metabolites were identified by comparing the mass spectra

180 and retention indices of the NIST Mass spectral search tool (version 2.0, Gaithersburg, MD, USA) with
181 Thermo Xcalibur software's automatic peak detection. The fluoranthene internal standard intensity
182 standardized the metabolite data (Jung et al., 2023; Ku et al., 2023; Liu et al., 2023; Muhizi et al., 2022).

183

184 **Isolation of primary intestinal epithelial cells and adhesion assay**

185 The experiment began with the retrieval of intestines, which were then placed in ice-cold HBSS devoid
186 of Mg and Cl ions (Gibco, NY, USA). These intestines underwent meticulous cleaning to eliminate
187 mesenteric fat and external mucus. Subsequently, the duodenal tract was harvested, longitudinally opened,
188 cut into 1-2 mm pieces, and rinsed in ice-cold HBSS. The prepared tissue pieces underwent a 30-minute
189 digestion at 37 °C using digestion medium. After the digestion process, the tissue was subjected to
190 centrifugation at 100 × g for 3 min, and the resulting pellet was resuspended in a 37 °C washing medium.

191 The resuspended pellet was subsequently filtered through a 100 µm cell strainer, followed by a second
192 filtration using a 40 µm cell strainer in reverse. The aggregates recovered from the filtration were
193 resuspended in basal medium. These aggregates were then diluted to a concentration of 0.8 mg/ml, with a
194 density of 1000 aggregates per well, and plated in 24-well plates coated with a Matrigel matrix (Corning,
195 NY, USA). The cells were cultured at 37 °C with 5% CO₂ for 24 h. During this time, the cell clusters were
196 identified, and the degree of endothelial cell contamination was assessed. The cultures were meticulously
197 washed with HBSS to eliminate unattached and dead cells, and any foci of proliferating enterocytes were
198 replenished with fresh medium. Different growth factors were introduced at specific time points following
199 seeding. For passaging, trypsin-EDTA was employed, and the cells were seeded into newly coated wells at
200 a density of 3.5x10⁵ cells per cm² (Ghiselli et al., 2021; Marks et al., 2022).

201 Before the adhesion assay, primary cell monolayers were washed 3 times with PBS to remove culture
202 medium and nonattached cells. Bacterial strains were treated with medium without FBS and incubated at
203 37 °C for 2 h in an atmosphere of 5% CO₂. After 2 h, the monolayers were washed 5 times with PBS to
204 remove the nonattached bacteria. The attached cells were lysed using trypsin-EDTA. Serial dilutions of the
205 mixture were plated on MRS agar and incubated at 37 °C for 48 h. The adhesion ability was determined by

206 counting CFU/mL. *Lacticaseibacillus rhamnosus* GG was used as a positive control.

207

208 **Statistics**

209 This study used triplicate data points, expressed as the mean \pm standard deviation, and determined
210 significant differences using Student's t test, one-way ANOVA, and SigmaPlot 13 (GraphPad Software,
211 CA, USA), followed by Tukey's post hoc test. The abundance of metabolites of each sample was analyzed
212 using the M²IA server (<http://m2ia.met-bioinformatics.cn/>) and MetaboAnalyst 5.0
213 (<https://www.metaboanalyst.ca>).

214

ACCEPTED

Results and discussion

Metagenomic and culturomic analysis of domestic canines

To identify prospective probiotic candidates that may be beneficial to canines, we compared the culture-dependent and culture-independent gut microbiota of domestic canines. In pursuit of practical insights in culturomic analysis, an assortment of 138 distinct lactic acid bacteria was collected from three distinct media types. These isolates belonged to twenty different species. Fig. 1A illustrates that the four predominant bacterial species were as follows: *Enterococcus hirae* (5.1%), *Lactobacillus acidophilus* (21.7%), *Lactobacillus agilis* (13.8%), and *Ligilactobacillus animalis* (6.5%). We determined that the potential spectrum of probiotics should be restricted to *Lactobacillus* species, as they comprised the majority of the bacteria that were isolated (Fig. 1B, C). To achieve this, we monitored the number of *Lactobacillus* species that overlapped between the culturomic and metagenomics methodologies. As shown in a Venn diagram (Fig. 1D), four species of *Lactobacillus* (*L. acidophilus*, *L. amylolyticus*, *L. fermentum*, and *L. murinus*) were identified through both culturomic and metagenomics analyses. In light of this result, we sought to investigate what probiotic changes *L. acidophilus* SLAM AK001, which has the highest proportion, could make through FIMM incubation.

FIMM incubation increased the microbial diversity

The study meticulously analyzed the effects of FIMM incubation on microbial diversity by integrating specific canine-derived probiotics, *L. acidophilus* SLAM AK001, and marketed probiotics, *E. faecium* IDCC 2102, and *B. lactis* IDCC 4301 were integrated into the FIMM system with fecal samples from laboratory-raised beagles to simulate the gut environment and assess the ensuing microbial alterations. Utilizing next-generation sequencing, the research identified a comprehensive array of 46,016 operational taxonomic units (OTUs) and 872 distinct taxonomic bacterial entities. Through the application of the alpha-diversity index, specifically the Chao and Shannon indices, a significant elevation in species diversity was observed (Chao and Shen, 2003). The Chao index revealed a $46.9 \pm 7.4\%$ enhancement in mean species diversity attributable to the FIMM incubation, with an additional increase of $103.6 \pm 31.6\%$ following

242 probiotic supplementation. Concurrently, the Shannon index recorded a $23.83 \pm 5.1\%$ rise in diversity post-
243 FIMM incubation, and a further augmentation of $66.1 \pm 1.8\%$ with the introduction of probiotics (Fig. 2A).
244 Moreover, the diversified microbiota was found to be unique to each other according to the beta diversity
245 analysis. Unweighted and weighted UniFrac used in beta diversity represent qualitative and quantitative
246 variants, respectively. Each plot represents a relative abundance of species of a group, and the distance
247 between the plots represents distinctiveness (Koleff et al., 2003). From our study, the beta diversity analysis,
248 employing both unweighted and weighted UniFrac methods, illustrated distinctive microbial assemblages
249 resulting from FIMM incubation relative to the control, and a unique microbial configuration associated
250 with the probiotic intervention (Fig. 2B). These results highlight the FIMM system's capability to not only
251 enhance microbial diversity but also to cultivate specific microbial community contingent on the introduced
252 probiotic strains.

253 The supplementation with probiotics plays a pivotal role in enhancing the diversity of gut microbiota, a
254 factor that is intrinsically linked to the overall health of the host. The gut microbiota's diversity is crucial,
255 starting with its fundamental role in the digestion and absorption of nutrients. The myriad of
256 microorganisms residing in the gastrointestinal tract play a critical role in breaking down a broad spectrum
257 of dietary fibers and nutrients, leading to enhanced nutrient uptake and improved digestive efficiency (Yu
258 et al., 2022; Zhong et al., 2023). This microbial diversity extends its benefits beyond digestion to bolster
259 the immune system. It orchestrates a range of immune responses, strengthening the host's defense
260 mechanisms against opportunistic and pathogenic microbes. The balanced interplay among various
261 microbial strains is also vital for regulating inflammatory processes, potentially reducing the incidence of
262 inflammation-related disorders and supporting metabolic health and weight management (Kim et al., 2020;
263 Liu et al., 2018; Ritchie and Romanuk, 2012; Sánchez et al., 2017). The FIMM experiments provided
264 insightful data, demonstrating that the in vitro fermentation process could enrich the diversity of bacterial
265 strains within the canine gut microbiota. This enhancement closely mirrors the beneficial effects observed
266 with probiotic consumption in vivo. The distinctive clustering patterns observed in the FIMM system,
267 which varied with each bacterial strain, offer evidence of the system's ability to foster specific interactions
268 and associations within the microbial community. These findings underscore the potential of FIMM as a

269 valuable model for exploring the intricate dynamics of gut microbiota and the impact of probiotics, offering
270 a deeper understanding of how probiotic supplementation can modulate microbial ecosystems to support
271 host health.

272

273 **FIMM incubation altered the microbial composition**

274 The investigation into the impact of the FIMM incubation on microbial composition revealed significant
275 alterations in the fecal microbiota, which might have been affected during sample collection. An in-depth
276 examination of the 15 most abundant genera demonstrated that FIMM incubation induced notable changes
277 in microbial composition. Specifically, when the FIMM system was supplemented with probiotics *L.*
278 *acidophilus* SLAM AK001, *E. faecium* IDCC 2102, and *B. lactis* IDCC 4301, there was a substantial shift
279 in microbial communities compared to the control group. Probiotics significantly increased the populations
280 of *Ruminococcus*, *Blautia*, *Dorea*, and lactic acid bacteria, such as *Lactobacillus* and *Faecalibacterium*
281 (Grześkowiak et al., 2015; Lee et al., 2022a). These genera are recognized as beneficial commensal
282 probiotics in canines. Concurrently, there was a reduction in the abundance of potential opportunistic
283 pathogens, including *Clostridium* (Ghose, 2013), *Streptococcus* (Xu et al., 2007), and *Prevotella* (Larsen,
284 2017) (Fig. 2C), showcasing the probiotics' ability to modulate the gut microbiota favorably. Noteworthy
285 is the observation that the microbial changes induced by *L. acidophilus* SLAM AK001 were in alignment
286 with those noted in an in vivo canine model previously studied by our group (Kang et al., 2024; Kang et
287 al., 2022), suggesting that this strain's effects are consistent across different experimental settings. This
288 consistency enhances the validation of the FIMM system as a reliable model for studying probiotic effects.

289 *Lactobacillus*, *Bifidobacterium*, and *Enterococcus* are well-established probiotics. In a prior study,
290 supplementation with *Lactobacillus* and *Bifidobacterium* was found to reduce *Clostridium* and increase
291 commensal bacteria such as *Faecalibacterium* and *Lactobacillus* in individuals with conditions such as
292 diarrhea, inflammatory bowel diseases, and colorectal cancer (Alcon-Giner et al., 2020; Gerasimov et al.,
293 2016; Lopez-Siles et al., 2017). While research in canines is relatively limited compared to human studies,
294 the administration of *Enterococcus faecium* and *Bifidobacterium* in canines also resulted in an increase in
295 *Lactobacillus*, *Enterococcus*, and *Enterobacteriaceae* while reducing the presence of *Salmonella*,

296 *Campylobacter*, and *Clostridium* (Sabbioni et al., 2016; Vahjen and Männer, 2003). The FIMM cultivation
297 method employed in this study mimics the probiotic effects of *L. acidophilus* SLAM AK001, *E. faecium*
298 IDCC 2102, and *B. lactis* IDCC4301, as observed in real-life scenarios where they are administered to
299 mammals. This underscores the reliability of the FIMM in vitro cultivation system.

300 Overall, the FIMM system's ability to mimic real-life probiotic effects in an in vitro setting underscores
301 its potential as a valuable tool for exploring the intricate dynamics of gut microbiota and assessing the
302 impacts of various probiotic strains on microbial communities. This system offers a promising avenue for
303 advancing our understanding of probiotic interactions within the gut ecosystem, providing insights that
304 could inform the development of targeted probiotic therapies for canines.

305

306 **FIMM incubation can imply changes in intestinal robustness**

307 Additionally, the FIMM incubation process not only influenced the microbial composition but also
308 significantly impacted the metabolic profile within the system, suggesting changes in intestinal robustness.
309 Detailed metabolic analysis categorized nine distinct types of metabolites: alcohols, alkylamines, amino
310 acids, carbohydrates, fatty acids, indoles, lipids, nucleotides, organic acids, and others. Remarkably,
311 compared to the control group, the introduction of probiotics led to an overall increase in these metabolites,
312 with notable surges in amino acids and organic acids, including 4-hydroxybutyric acid, L-norleucine, and
313 isovaleric acid. This metabolic enhancement, particularly in essential amino acids such as isoleucine,
314 leucine, lysine, methionine, phenylalanine, and valine, underscores the broad-reaching impact of probiotics
315 on metabolic processes. These amino acids are vital for protein synthesis across all living organisms,
316 indicating a systemic effect of probiotic treatment on fundamental biological functions (Amorim Franco
317 and Blanchard, 2017; Neis et al., 2015; Oh et al., 2021; Yoo et al., 2022). Organic acids, integral to primary
318 metabolism, play pivotal roles in various biochemical pathways (Ramachandran et al., 2006; Sauer et al.,
319 2008; Vasquez et al., 2022). The FIMM incubation results showed that probiotic administration could
320 influence the production of key organic acids like propionic acid, acetic acid, and lactic acid (Fig. 3). These
321 acids are crucial for numerous metabolic processes, including energy production and regulatory functions
322 within the gut environment.

323 *Bifidobacterium* plays a significant role in the fermentation of dietary fibers and carbohydrates, resulting
324 in the production of short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate. These
325 SCFAs offer various health benefits, including serving as an energy source for colonocytes, promoting
326 gastrointestinal health, and exhibiting anti-inflammatory properties (Kim et al., 2022). *Bifidobacterium*, as
327 a type of lactic acid bacteria, generates lactic acid as a metabolic byproduct, which contributes to the
328 maintenance of an acidic gut environment, thereby restraining the proliferation of pathogenic
329 microorganisms (de Souza Oliveira et al., 2012; Pokusaeva et al., 2011). Moreover, select strains of
330 *Bifidobacterium* have the capacity to synthesize gamma-aminobutyric acid (GABA), a neurotransmitter
331 with potential anxiolytic and calming effects on the central nervous system (Duranti et al., 2020).

332 Likewise, *E. faecium*, another beneficial gut bacterium, also generates lactic acid as a predominant
333 metabolic byproduct, reinforcing the acidic conditions of the gut, which can inhibit the proliferation of
334 pathogenic bacteria. In addition, *E. faecium* can participate in the production of various SCFAs, including
335 acetate, propionate, and butyrate, each of which has multiple health advantages, particularly in the context
336 of gut health. *E. faecium* is also involved in the digestion and metabolic breakdown of dietary proteins,
337 giving rise to the production of diverse amino acids (Allameh et al., 2017; Wang et al., 2020).

338 Finally, *L. acidophilus* primarily produces lactic acid as part of its metabolic processes, supporting the
339 creation of an acidic gut environment that impedes the growth of detrimental bacteria and pathogens. While
340 *L. acidophilus* SLAM AK001 may not be as widely recognized for its SCFA production as certain other
341 bacterial strains, it does contribute to the production of SCFAs, particularly acetate and propionate
342 (Chamberlain et al., 2022; Hossain et al., 2021). These findings underscore the significance of the
343 metabolites generated within the FIMM cultivation system, demonstrating that the in vitro cultivation
344 system provides the conditions necessary for proper metabolite production by different bacterial species.

345 The observed metabolic changes within the FIMM system, prompted by probiotic supplementation,
346 mirror the potential enhancements in intestinal robustness and metabolic activity, which could have
347 significant implications for gut health and overall organismal well-being. This insight into the metabolic
348 alterations provides a deeper understanding of the multifaceted impacts of probiotics, extending beyond

349 microbial diversity to include metabolic function, thereby offering a comprehensive view of the probiotic
350 influence on the gut ecosystem.

351

352 **Probiotics for canines were very specific for canine primary intestinal epithelial cells.**

353 In the conclusive segment of the study, an in-depth evaluation was conducted to ascertain the host
354 specificity of the lactic acid bacteria used, a factor that is paramount in determining their potential
355 effectiveness as probiotics in canine hosts. Host specificity is a critical attribute that influences a bacterium's
356 ability to colonize and thrive within a specific host, impacting its probiotic efficacy and interaction with the
357 host's gut microbiome (Chaib De Mares et al., 2017; Dogi and Perdigón, 2006). To assess this, a series of
358 host specificity tests were carried out using primary intestinal epithelial cells derived from a diverse array
359 of species, including but not limited to dogs, chickens, laying hens, humans, and pigs. The aim was to
360 investigate the cell adhesion capabilities of the probiotic strains, which is indicative of their potential to
361 colonize and establish within the host's gastrointestinal tract effectively. The study utilized the control strain,
362 *L. rhamnosus* GG, known for its broad host specificity, as a comparative baseline, exhibiting an $88.3 \pm 0.7\%$
363 specificity rate across various cell types. A significant affinity for primary intestinal epithelial cells sourced
364 from canines was observed among the probiotic strains, an insight depicted in Figure 4. This pronounced
365 host specificity suggests these probiotics are well-suited for adherence and potential colonization within
366 the canine gut. Specifically, *L. acidophilus* SLAM showcased the most substantial host specificity, with a
367 rate of $81.3 \pm 2.7\%$ when interacting with canine cells. Similarly, *E. faecium* IDCC 2102 and *B. lactis* IDCC
368 4301 exhibited host specificity rates of $86.2 \pm 1.9\%$ and $88.3 \pm 0.6\%$, respectively, with canine cells (Figure
369 4A). Notably, these strains maintained cell counts comparable to the original CFU (colony-forming units)
370 before inoculation, underscoring their strong adherence capabilities to canine primary intestinal cell lines.
371 Further analysis revealed that beyond canine cells, *L. acidophilus* SLAM AK001, *E. faecium* IDCC 2102,
372 and *B. lactis* IDCC 4301 displayed host specificity rates of $74.5 \pm 6.2\%$, $64.4 \pm 13.4\%$, and $75.0 \pm 9.5\%$,
373 respectively, towards other primary intestinal epithelial cells. A marked decrease in cell adhesion capacity
374 was noted in avian primary enterocytes compared to the initial CFU counts, highlighting a more constrained
375 host specificity in these cell types (Figure 4B-D). This detailed examination underlines the significant host

376 specificity of canine-derived probiotics, positioning them as potent candidates for in-depth in vivo studies.
377 Their targeted adherence to canine intestinal cells intimates that these probiotics may confer specific health
378 benefits tailored to canines, underscoring their potential value in veterinary care and probiotic formulation
379 development.
380

ACCEPTED

381

Conclusion

382 To conclude, this study was initiated with the objective of mitigating the limitations associated with
383 microbial research in live animals while identifying potential probiotics beneficial for canines. Although
384 animal studies are pivotal in scientific discovery and pharmaceutical advancements, they are fraught with
385 ethical dilemmas and practical challenges. There's a pronounced emphasis on animal welfare, emphasizing
386 the reduction of animal distress and the pursuit of alternatives to circumvent the need for animal sacrifice,
387 a subject of considerable ethical discourse. Yet, the development of in vitro methodologies capable of fully
388 emulating the living conditions of organisms remains nascent, with a clear demand for further exploration
389 and standardization in this domain.

390 Thus, the core ambition of this research was to introduce and validate a standardized in vitro cultivation
391 approach, termed the FIMM system. This research effectively showcased the FIMM system's capability to
392 replicate the complex interactions between gut bacteria and their host, reflecting the dynamics observed
393 when probiotics, specifically *L. acidophilus* SLAM AK001, *E. faecium* IDCC2102, and *B. lactis* IDCC4301,
394 derived from canine fecal samples, were introduced into the system. To claim that the FIMM system
395 perfectly emulates the canine gut microbiota system, it would have been ideal to administer these strains to
396 actual canines and observe the resultant effects, a step that represents a limitation in this study. Nonetheless,
397 the findings highlight the FIMM system's efficacy as a potent tool for in-depth gut microbiota research,
398 enhancing our comprehension of probiotics' impacts on animal health. This advancement not only facilitates
399 a more nuanced understanding of the gut microbiome but also opens avenues for developing targeted and
400 efficacious probiotic interventions in veterinary practice.

401

Acknowledgments

403 This research was supported by Ildong Bioscience Co., Ltd. (2022) and the National Research Foundation
404 of Korea Grant, funded by the Korean government (MEST) (NRF-2021R1A2C3011051) and by the support
405 of the "Cooperative Research Program for Agriculture Science and Technology Development (Project No.
406 PJ015865)" Rural Development Administration, Republic of Korea, and by the support of "Cooperative
407 Research Program for Agriculture Science and Technology Development (RS-2023-00230754)" Rural

408 Development Administration, Korea

409

ACCEPTED

- 412 Alcon-Giner C, Dalby MJ, Caim S, Ketskemety J, Shaw A, Sim K, Lawson MA, Kiu R, Leclaire
413 C, Chalklen L. 2020. Microbiota supplementation with bifidobacterium and lactobacillus
414 modifies the preterm infant gut microbiota and metabolome: An observational study. *Cell*
415 *Reports Medicine* 1.
- 416 Allameh SK, Ringø E, Yusoff F, Daud HM, Ideris A. 2017. Dietary supplement of enterococcus
417 faecalis on digestive enzyme activities, short-chain fatty acid production, immune system
418 response and disease resistance of javanese carp (*puntius gonionotus*, bleeker 1850).
419 *Aquaculture Nutrition* 23:331-338.
- 420 Amorim Franco TM, Blanchard JS. 2017. Bacterial branched-chain amino acid biosynthesis:
421 Structures, mechanisms, and drugability. *Biochemistry* 56:5849-5865.
- 422 Chaib De Mares M, Sipkema D, Huang S, Bunk B, Overmann J, Van Elsas JD. 2017. Host
423 specificity for bacterial, archaeal and fungal communities determined for high-and low-
424 microbial abundance sponge species in two genera. *Frontiers in Microbiology* 8:2560.
- 425 Chamberlain M, O'flaherty S, Cobián N, Barrangou R. 2022. Metabolomic analysis of
426 lactobacillus acidophilus, l. Gasseri, l. Crispatus, and lacticaseibacillus rhamnosus strains
427 in the presence of pomegranate extract. *Frontiers in Microbiology* 13:863228.
- 428 Chao A, Shen T-J. 2003. Nonparametric estimation of shannon's index of diversity when there
429 are unseen species in sample. *Environmental and ecological statistics* 10:429-443.
- 430 Cho H-W, Choi S, Seo K, Kim KH, Jeon J-H, Kim CH, Lim S, Jeong S, Chun JL. 2022. Gut
431 microbiota profiling in aged dogs after feeding pet food contained *hericium*
432 *erinaceus*. *Journal of Animal Science and Technology* 64:937-949.
- 433 Choi YJ, Jin HY, Yang HS, Lee SC, Huh CK. 2016. Quality and storage characteristics of yogurt
434 containing *lacobacillus sakei* ali033 and cinnamon ethanol extract.
435 *Journal of Animal Science and Technology* 58:16.
- 436 De Souza Oliveira RP, Perego P, De Oliveira MN, Converti A. 2012. Growth, organic acids
437 profile and sugar metabolism of bifidobacterium lactis in co-culture with streptococcus
438 thermophilus: The inulin effect. *Food research international* 48:21-27.
- 439 Dogi CA, Perdigón G. 2006. Importance of the host specificity in the selection of probiotic
440 bacteria. *Journal of Dairy Research* 73:357-366.
- 441 Duranti S, Ruiz L, Lugli GA, Tames H, Milani C, Mancabelli L, Mancino W, Longhi G,
442 Carnevali L, Sgoifo A. 2020. Bifidobacterium adolescentis as a key member of the
443 human gut microbiota in the production of gaba. *Scientific reports* 10:14112.
- 444 Edgar RC. 2018. Updating the 97% identity threshold for 16s ribosomal rna otus. *Bioinformatics*
445 34:2371-2375.
- 446 Gerasimov S, Ivantsiv V, Bobryk L, Tsitsura O, Dedyshin L, Guta N, Yandyo B. 2016. Role of
447 short-term use of l. Acidophilus dds-1 and b. Lactis uabla-12 in acute respiratory
448 infections in children: A randomized controlled trial. *European journal of clinical*
449 *nutrition* 70:463-469.
- 450 Ghiselli F, Rossi B, Felici M, Parigi M, Tosi G, Fiorentini L, Massi P, Piva A, Grilli E. 2021.
451 Isolation, culture, and characterization of chicken intestinal epithelial cells. *BMC*
452 *Molecular and Cell Biology* 22:12.
- 453 Ghose C. 2013. Clostridium difficile infection in the twenty-first century. *Emerging Microbes &*
454 *Infections* 2:1-8.

455 Grześkowiak Ł, Endo A, Beasley S, Salminen S. 2015. Microbiota and probiotics in canine and
456 feline welfare. *Anaerobe* 34:14-23.

457 Harel M, Tang Q. 2023. Protection and delivery of probiotics for use in foods. In
458 Microencapsulation in the food industry. Elsevier.

459 Hossain MI, Kim K, Mizan MFR, Tousehik SH, Ashrafudoulla M, Roy PK, Nahar S, Jahid IK,
460 Choi C, Park SH. 2021. Comprehensive molecular, probiotic, and quorum-sensing
461 characterization of anti-listerial lactic acid bacteria, and application as bioprotective in a
462 food (milk) model. *Journal of Dairy Science* 104:6516-6534.

463 Javdan B, Lopez JG, Chankhamjon P, Lee Y-CJ, Hull R, Wu Q, Wang X, Chatterjee S, Donia
464 MS. 2020. Personalized mapping of drug metabolism by the human gut microbiome. *Cell*
465 181:1661-1679. e1622.

466 Jung HY, Lee HJ, Lee HJ, Kim YY, Jo C. 2023. Exploring effects of organic selenium
467 supplementation on pork loin: Se content, meat quality, antioxidant capacity, and
468 metabolomic profiling during storage. *Journal of Animal Science and Technology*.

469 Kang A, Kwak M-J, Lee DJ, Lee JJ, Kim MK, Song M, Lee M, Yang J, Oh S, Kim Y. 2024.
470 Dietary supplementation with probiotics promotes weight loss by reshaping the gut
471 microbiome and energy metabolism in obese dogs. *Microbiology Spectrum*:e02552-
472 02523.

473 Kang AN, Mun D, Ryu S, Lee JJ, Oh S, Kim MK, Song M, Oh S, Kim Y. 2022. Culturomic,
474 metagenomic, and transcriptomic-based characterization of commensal lactic acid
475 bacteria isolated from domestic dogs using *caenorhabditis elegans* as a model for aging.
476 *Journal of Animal Science*.

477 Kim J-Y, Kim JY, Kim H, Moon EC, Heo K, Shim J-J, Lee J-L. 2022. Immunostimulatory
478 effects of dairy probiotic strains *bifidobacterium animalis* ssp.
479 *lactis* hy8002 and *lactobacillus plantarum* hy7717.
480 *Journal of Animal Science and Technology* 64:1117-1131.

481 Kim T-R, Choi K-S, Ji Y, Holzapfel WH, Jeon M-G. 2020. Anti-inflammatory effects of
482 *lactobacillus reuteri* lm1071 via map kinase pathway in il-1 β -induced ht-
483 29 cells. *Journal of Animal Science and Technology* 62:864-874.

484 Koleff P, Gaston KJ, Lennon JJ. 2003. Measuring beta diversity for presence-absence data.
485 *Journal of Animal Ecology* 72:367-382.

486 Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a dual-
487 index sequencing strategy and curation pipeline for analyzing amplicon sequence data on
488 the miseq illumina sequencing platform. *Applied and environmental microbiology*
489 79:5112-5120.

490 Ku M-J, Miguel MA, Kim S-H, Jeong C-D, Ramos SC, Son AR, Cho Y-I, Lee S-S, Lee S-S.
491 2023. Effects of italian ryegrass silage-based total mixed ration on rumen fermentation,
492 growth performance, blood metabolites, and bacterial communities of growing hanwoo
493 heifers. *Journal of Animal Science and Technology* 65:951-970.

494 Larsen JM. 2017. The immune response to prevotella bacteria in chronic inflammatory disease.
495 *Immunology* 151:363-374.

496 Lee D, Goh TW, Kang MG, Choi HJ, Yeo SY, Yang J, Huh CS, Kim YY, Kim Y. 2022a.
497 Perspectives and advances in probiotics and the gut microbiome in companion animals.
498 *Journal of Animal Science and Technology* 64:197-217.

499 Lee JH, Kim S, Kim ES, Keum GB, Doo H, Kwak J, Pandey S, Cho JH, Ryu S, Song M. 2022b.
500 Comparative analysis of the pig gut microbiome associated with the pig growth
501 performance. *Journal of Animal Science and Technology*.

502 Lee JH, Kim S, Kim ES, Keum GB, Doo H, Kwak J, Pandey S, Cho JH, Ryu S, Song M, Cho
503 JH, Kim S, Kim HB. 2023. Comparative analysis of the pig gut microbiome associated
504 with the pig growth performance. *Journal of Animal Science and Technology* 65:856-
505 864.

506 Liu J, Wang K, Zhao L, Li Y, Li Z, Li C. 2023. Investigation of supplementation with a
507 combination of fermented bean dregs and wheat bran for improving the growth
508 performance of the sow. *Journal of Animal Science and Technology*.

509 Liu Y, Tran DQ, Rhoads JM. 2018. Probiotics in disease prevention and treatment. *The Journal*
510 *of Clinical Pharmacology* 58:S164-S179.

511 Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. 2017. Faecalibacterium
512 prausnitzii: From microbiology to diagnostics and prognostics. *The ISME journal*
513 11:841-852.

514 Marks H, Grześkowiak Ł, Martinez-Vallespin B, Dietz H, Zentek J. 2022. Porcine and chicken
515 intestinal epithelial cell models for screening phytogetic feed additives-chances and
516 limitations in use as alternatives to feeding trials. *Microorganisms* 10.

517 Mugwanya M, Dawood MA, Kimera F, Sewilam H. 2021. Updating the role of probiotics,
518 prebiotics, and synbiotics for tilapia aquaculture as leading candidates for food
519 sustainability: A review. *Probiotics and Antimicrobial Proteins*:1-28.

520 Muhizi S, Cho S, Palanisamy T, Kim IH. 2022. Effect of dietary salicylic acid supplementation
521 on performance and blood metabolites of sows and their litters. *Journal of Animal*
522 *Science and Technology* 64:707-716.

523 Mun D, Kim H, Shin M, Ryu S, Song M, Oh S, Kim Y. 2021. Decoding the intestinal microbiota
524 repertoire of sow and weaned pigs using culturomic and metagenomic approaches.
525 *Journal of Animal Science and Technology* 63:1423-1432.

526 Neis EP, Dejong CH, Rensen SS. 2015. The role of microbial amino acid metabolism in host
527 metabolism. *Nutrients* 7:2930-2946.

528 Oh JK, Vasquez R, Kim SH, Hwang I-C, Song JH, Park JH, Kim IH, Kang D-K. 2021.
529 Multispecies probiotics alter fecal short-chain fatty acids and lactate levels in weaned
530 pigs by modulating gut microbiota. *Journal of Animal Science and Technology* 63:1142-
531 1158.

532 Pokusaeva K, Fitzgerald GF, Van Sinderen D. 2011. Carbohydrate metabolism in bifidobacteria.
533 *Genes & nutrition* 6:285-306.

534 Quinn PJ, Markey BK, Leonard F, Fitzpatrick E, Fanning S. 2015. Concise review of veterinary
535 microbiology.

536 Ramachandran S, Fontanille P, Pandey A, Larroche C. 2006. Gluconic acid: Properties,
537 applications and microbial production. *Food Technology & Biotechnology* 44.

538 Ritchie ML, Romanuk TN. 2012. A meta-analysis of probiotic efficacy for gastrointestinal
539 diseases. *PloS one* 7:e34938.

540 Sabbioni A, Ferrario C, Milani C, Mancabelli L, Riccardi E, Di Ianni F, Beretti V, Superchi P,
541 Ossiprandi MC. 2016. Modulation of the bifidobacterial communities of the dog
542 microbiota by zeolite. *Frontiers in Microbiology* 7:1491.

543 Sagawa K, Li F, Liese R, Sutton SC. 2009. Fed and fasted gastric pH and gastric residence time
544 in conscious beagle dogs. *Journal of pharmaceutical sciences* 98:2494-2500.

545 Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. 2017.
546 Probiotics, gut microbiota, and their influence on host health and disease. *Molecular*
547 *nutrition & food research* 61:1600240.

548 Sauer M, Porro D, Mattanovich D, Branduardi P. 2008. Microbial production of organic acids:
549 Expanding the markets. *Trends in biotechnology* 26:100-108.

- 550 Son S, Lee R, Park S-M, Lee SH, Lee H-K, Kim Y, Shin D. 2021. Complete genome sequencing
551 and comparative genomic analysis of *Lactobacillus acidophilus* c5 as a potential canine
552 probiotics. *Journal of Animal Science and Technology* 63:1411.
- 553 Song D, Lee J, Yoo Y, Oh H, Chang S, An J, Park S, Jeon K, Cho Y, Yoon Y, Cho J. 2023.
554 Effects of probiotics on growth performance, intestinal morphology, intestinal microbiota
555 weaning pig challenged with *Escherichia coli* and *Salmonella enterica*. *Journal of Animal
556 Science and Technology*.
- 557 Sornplang P, Piyadeatsoontorn S. 2016. Probiotic isolates from unconventional sources: A
558 review. *Journal of Animal Science and Technology* 58:26.
- 559 Tochio T, Makida R, Fujii T, Kadota Y, Takahashi M, Watanabe A, Funasaka K, Hirooka Y,
560 Yasukawa A, Kawano K. 2022. The bacteriostatic effect of erythritol on canine
561 periodontal disease-related bacteria. *Polish Journal of Veterinary Sciences* 25:75-82.
- 562 Vahjen W, Männer K. 2003. The effect of a probiotic *Enterococcus faecium* product in diets of
563 healthy dogs on bacteriological counts of *Salmonella* spp., *Campylobacter* spp. and
564 *Clostridium* spp. in faeces. *Archives of Animal Nutrition* 57:229-233.
- 565 Van De Wiele T, Van Den Abbeele P, Ossieur W, Possemiers S, Marzorati M. 2015. The
566 simulator of the human intestinal microbial ecosystem (SHIME®). *The Impact of Food
567 Bioactives on Health: in vitro and ex vivo models*:305-317.
- 568 Vasquez R, Oh JK, Song JH, Kang D-K. 2022. Gut microbiome-produced metabolites in pigs: A
569 review on their biological functions and the influence of probiotics. *Journal of Animal
570 Science and Technology* 64:671-695.
- 571 Wang W, Cai H, Zhang A, Chen Z, Chang W, Liu G, Deng X, Bryden WL, Zheng A. 2020.
572 *Enterococcus faecium* modulates the gut microbiota of broilers and enhances phosphorus
573 absorption and utilization. *Animals* 10:1232.
- 574 Xu P, Alves JM, Kitten T, Brown A, Chen Z, Ozaki LS, Manque P, Ge X, Serrano MG, Puiu D.
575 2007. Genome of the opportunistic pathogen *Streptococcus sanguinis*. *Journal of
576 bacteriology* 189:3166-3175.
- 577 Yoo J, Lee J, Zhang M, Mun D, Kang M, Yun B, Kim Y-A, Kim S, Oh S. 2022. Enhanced γ -
578 aminobutyric acid and sialic acid in fermented deer antler velvet and immune promoting
579 effects. *Journal of Animal Science and Technology* 64:166-182.
- 580 Yu DY, Oh S-H, Kim IS, Kim GI, Kim JA, Moon YS, Jang JC, Lee SS, Jung JH, Park J, Cho
581 KK. 2022. Intestinal microbial composition changes induced by *Lactobacillus
582 plantarum* gbl 16, 17 fermented feed and intestinal immune homeostasis
583 regulation in pigs. *Journal of Animal Science and Technology* 64:1184-1198.
- 584 Zhong Y, Zuo B, Li J, Zhai Y, Mudarra R. 2023. Effects of paraformic acid supplementation, as
585 an antibiotic replacement, on growth performance, intestinal morphology and gut
586 microbiota of nursery pigs. *Journal of Animal Science and Technology*.

588

589

Figure legends

590

591 **Fig. 1 The comparison of culturomic and metagenomic characterization of domestic canine fecal**
592 **microbiota.** (A) This list presents the bacteria isolated from canine feces, utilizing the aforementioned
593 medium. Subsequent to the isolation, the compositions specific to *Lactobacillus* were subjected to further
594 examination employing (B) culturomic and (C) metagenomic analyses. (D) A Venn diagram elucidates the
595 distribution of *Lactobacillus* species, categorized by those identified through culturomics (purple),
596 metagenomics (yellow), and the species identified by both methods (orange).

597

598 **Fig. 2 The diversity and richness of fecal microbiota was altered through FIMM incubation with**
599 **probiotics.** The metagenomic analysis was utilized to elucidate the alterations in bacterial relative
600 abundance subsequent to FIMM cultivation. Comparative analysis was conducted between FIMM
601 cultivations subjected to probiotic interventions (LA, 2102, and 4301) and a control cohort devoid of any
602 treatment (cont). (A) Indices of alpha diversity and (B) Principal Coordinates Analysis (PCoA) diagrams
603 were constructed to elucidate the spatial distribution of fecal microbiome samples. These diagrams plot
604 individual samples, with axes representing the principal dimensions capturing the maximal variance in
605 microbial community structure across the groups. (C) The comparative representation of bacterial relative
606 abundance at phylum, family, and genus levels across all groups was meticulously quantified. All values
607 are expressed as the mean±SD; significant differences were determined using Student's t test and ANOVA
608 compared to the cont at * $P < 0.05$ and *** $P < 0.001$. LA, *Lactobacillus acidophilus* SLAM AK001; 2102,
609 *Enterococcus faecium* IDCC 2102; 4301, *Bifidobacterium lactis* IDCC 4301.

610

611 **Fig. 3 Comparative analysis of unique metabolite production by probiotics in FIMM.** Following the
612 FIMM cultivation, variations in metabolite profiles across different groups were examined. (A) In the PCA
613 score plots, the analysis revealed that fecal samples from groups subjected to probiotic interventions (LA,
614 2102, and 4301) clustered together, indicating a shared metabolic response. In contrast, the control group
615 was distinctly clustered, highlighting significant metabolic differentiation from the treated groups. (B) The

616 Partial least squares discriminant analysis (PLS-DA) further analyzed these differences, identifying
617 metabolites that drove the separation between treated and untreated groups. Additionally, the colored boxes
618 in (B) and (C) categorized the top 50 abundant metabolites, with varying colors denoting concentration
619 levels, offering an understanding of metabolite fluctuations resulting from FIMM cultivation and probiotic
620 treatments. LA, *Lactobacillus acidophilus* SLAM AK001; 2102, *Enterococcus faecium* IDCC 2102; 4301,
621 *Bifidobacterium lactis* IDCC 4301.


622

623 **Fig. 4 Canine probiotics were highly selective to canine primary intestinal epithelial cells.**

624 To investigate the host specificity of the probiotics, a cell adhesion assay was performed utilizing (A) canine
625 primary intestinal epithelial cells, (B) porcine primary intestinal epithelial cells, and (C, D) avian primary
626 intestinal epithelial cells. The assay determined host specificity by comparing the percentage of bacterial
627 colony-forming units (CFUs) before and after a two-hour exposure to the seeded cells in 24-well plates.
628 The blue bars in the graphical representation denote the CFU count of bacteria prior to exposure to each
629 type of cell, while the purple bars indicate the CFU count of bacteria retrieved after the exposure. Each cell
630 adhesion assay was conducted in triplicate wells. All values are expressed as the mean \pm SD; significant
631 differences were determined using Student's t test and ANOVA, with each treatment's data at 2 hours
632 compared to the baseline at 0 hour by **** $P < 0.0001$. LA, *Lactobacillus acidophilus* SLAM AK001;
633 2102, *Enterococcus faecium* IDCC 2102; 4301; *Bifidobacterium lactis* IDCC 4301; LGG, *Lacticaseibacillus*
634 *rhamnosus* GG.

635

(A)
Canine microbiome



- *Lactobacillus acidophilus*
- *Lactobacillus agilis*
- *Lactobacillus amylolyticus*
- *Ligilactobacillus animalis*
- *Limosilactobacillus fermentum*
- *Lactobacillus johnsonii*
- *Lactobacillus murinus*
- *Lactobacillus reuteri*
- *Ligilactobacillus salivarius*
- *Enterococcus durans*
- *Enterococcus faecium*
- *Escherichia coli*
- *Enterococcus hirae*
- *Escherichia fergusonii*
- *Salmonella ap.*
- *Enterococcus villorum*
- *Streptococcus equinus*
- *Streptococcus infantarius*
- *Streptococcus lutetiensis*
- *Streptococcus gallolyticus*

(B)
Culturomics
Lactic acid bacteria




- *Lactobacillus acidophilus*
- *Lactobacillus agilis*
- *Lactobacillus amylolyticus*
- *Ligilactobacillus animalis*
- *Limosilactobacillus fermentum*
- *Lactobacillus johnsonii*
- *Lactobacillus murinus*
- *Lactobacillus reuteri*
- *Ligilactobacillus salivarius*

(C)
Metagenomics
Lactic acid bacteria




- *Lactobacillus amylolyticus*
- *Lactobacillus acidophilus*
- *Limosilactobacillus mucosae*
- *Lactobacillus gasseri*
- *Limosilactobacillus fermentum*
- *Lactobacillus plantarum*
- *Lactobacillus murinus*

(D)



636


637 **Fig. 1.**



638

639 **Fig. 2.**

640




641

642 **Fig. 3.**

643

644



645

646 **Fig. 4.**

647

648

649

650